DelveInsight’s, “Cyclin-Dependent Kinase Inhibitor Pipeline Insights 2026” report provides comprehensive insights about 45+ companies and 52+ pipeline drugs in Cyclin-Dependent Kinase Inhibitor pipeline landscape. It covers the Cyclin-Dependent Kinase Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cyclin-Dependent Kinase Inhibitor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Cyclin-Dependent Kinase Inhibitor Research @ Cyclin-Dependent Kinase Inhibitor Pipeline Outlook
Key Takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report
Stay informed about the cutting-edge advancements in Cyclin-Dependent Kinase Inhibitor treatments @ Cyclin-Dependent Kinase Inhibitor Clinical Trials Assessment
Cyclin-Dependent Kinase Inhibitor Overview
Cyclin-dependent kinase inhibitor protein (also known as CKIs, CDIs, or CDKIs) is a protein which inhibits the enzyme cycling-dependent kinase (CDK) and Cyclin activity by stopping the cell cycle if there are unfavorable conditions, therefore, acting as tumor suppressors. Cell cycle progression is stopped by Cyclin-dependent kinase inhibitor protein at the G1 phase. CKIs are vital proteins within the control system that point out whether the process of DNA synthesis, mitosis, and cytokines control one another. If a malfunction prevents the successful completion of DNA synthesis during the G1 phase, a signal is sent to delay or stop the progression to the S phase. Cyclin-dependent kinase inhibitor proteins are essential in the regulation of the cell cycle. If cell mutations surpass the cell cycle checkpoints during cell cycle regulation, it can result in various types of cancer. In the cyclin-dependent kinase (CDK) family or CDK, Cyclin, and CKIs, serine/threonine
Cyclin-Dependent Kinase Inhibitor Emerging Drugs Profile
Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency. These enzymes are responsible for phosphorylating and thus deactivating the retinoblastoma protein, which plays a role in cell cycle progression from the G1 (first gap) to the S (synthesis) phase. Blocking this pathway prevents cells from progressing to the S phase, thereby inducing apoptosis (cell death). In vitro analysis using cancer cell lines shows that abemaciclib induces non‐apoptotic cell death characterized by the formation of cytoplasmic vacuoles derived from lysosomes. The drug was approved for use in combination with endocrine therapy (such as tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. Currently, the drug is in the Phase III stage of its development for the treatment of Liposarcoma and Prostate cancer.
GFH009 is a potent and highly selective small-molecule inhibitor of CDK9 with more than 100 times selectivity over other CDK subtypes. Preclinical data have also suggested the potential anti-tumor effects of GFH009 in combination with BCL-2 inhibitors. As a potent and highly selective small molecule CDK9 inhibitor, GFH009 exhibits strong apoptosis-inducing and anti-proliferative activities in multiple human cell lines and animal models of diseases. It effectively inhibits the growth of tumor in various xenograft models and significantly improves survival of tumor bearing animals. The drug is currently in Phase II stage of Clinical trial evaluation for the treatment Hematological malignancies.
Enitociclib is a potent and selective CDK9 inhibitor currently in clinical development. The small molecule inhibitor targets P-TEFb/CDK9 and has shown robust pathway modulation as well as efficacy and safety in several preclinical tumor models and in early phase clinical studies. Enitociclib was identified as a top hit in small molecule inhibitor screening and exposure to Enitociclib for 96 hours against a representative panel of MM cell lines (NCI-H929, MM.1S, OPM-2, and U266B1) demonstrated significant cytotoxic activity, with IC50 values ranging from 36 to 78 nM. Vincerx Pharma is focused on Phase I/II study with the National Institutes of Health (NIH) evaluating combination of Enitociclib and Venetoclax and prednisone (VVIP) in diffuse large B-cell lymphoma (DLBCL) and peripheral T Cell Lymphoma (PTCL).
AVZO-021, also known as ARTS-021, is a promising clinical-stage drug developed by Avenzo Therapeutics, Inc. It is a highly potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2), primarily aimed at treating hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, as well as cancers with cyclin E1 (CCNE1) amplification. Currently, the drug is in the Phase I/II stage of its development for the treatment of triple negative breast cancer.
The Cyclin-Dependent Kinase Inhibitor Pipeline Report provides insights into
Learn more about Cyclin-Dependent Kinase Inhibitor Drugs opportunities in our groundbreaking research and development projects @ Cyclin-Dependent Kinase Inhibitor Unmet Needs
Cyclin-Dependent Kinase Inhibitor Companies
G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.
Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Cyclin-Dependent Kinase Inhibitor Products have been categorized under various Molecule types such as
Discover the latest advancements in Cyclin-Dependent Kinase Inhibitor treatment by visiting our website @ Cyclin-Dependent Kinase Inhibitor Market Drivers and Barriers, and Future Perspectives
Scope of the Cyclin-Dependent Kinase Inhibitor Pipeline Report
Read the full details of Cyclin-Dependent Kinase Inhibitor Pipeline on our website @ Cyclin-Dependent Kinase Inhibitor Emerging Drugs and Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/cyclin-dependent-kinase-inhibitor-pipeline-insight
